Table 4. Summary of adverse and serious adverse events.
All gradesGrade ≥3
Toca 511 and Toca FC
n = 27 n (%)
Lomustine
n = 84 n (%)
Toca 511 and Toca FC
n = 27 n (%)
Lomustine
n = 84 n (%)
Any treatment-emergent adverse event27 (100.0)70 (83.3)17 (63.0)45 (53.6)
Related treatment-emergent adverse event11 (40.7)52 (61.9)1 (3.7)31 (36.9)
Leading to study discontinuation treatment-emergent
adverse event
04 (4.8)04 (4.8)
Treatment-emergent serious adverse event9 (33.3)24 (28.6)7 (25.9)21 (25.0)
Related treatment-emergent serious adverse event2 (7.4)6 (7.1)1 (3.7)5 (6.0)